The "2nd China Pharmaceutical Innovation and Investment Conference" was held at the Suzhou Jinji Lake International Convention Center on October 29, 2017. Jiuzhang Biotech released the Phase I clinical trial data on the safety, tolerability and pharmacokinetics of CHA for injection in the treatment of advanced malignant gliomas.

Sichuan Jiuzhang Biotechnology Co., Ltd. has established a strategic technical research and development cooperation relationship with the Institute of Materia Medica of the Chinese Academy of Medical Sciences (affiliated to the Chinese Academy of Medical Sciences; its academic and professional title system falls under Peking Union Medical College, and it is a national key drug research institution). The two parties jointly established the "Chlorogenic Acid Cooperative Development Project Committee" to jointly conduct research on the pharmacological mechanism of chlorogenic acid and promote the transformation of basic research achievements into clinical applications.

In November 2016, the inventor Zhang Jie, Professor Chen Xiaoguang, the researcher of the anti-tumor mechanism of CHA, and Professor Li Wenbin, the main researcher of the glioma clinical research (PI), received an exclusive interview from the reporter of Nature magazine. The interview content was published in Nature on December 22, 2016.

hang Jie, the inventor (from Jiuzhang Biotech), released the clinical data of CHA for injection at the conference. The "China Pharmaceutical Innovation and Investment Conference" was held at the Suzhou Jinji Lake International Convention Center on November 14, 2016. Jiuzhang Biotech released the phased clinical research data of the CHA for injection preparation.

At the "China Pharmaceutical Innovation and Investment Conference", after the release of the Phase I clinical data (including the involved tumor spectrum and treatment trends) of the CHA injection developed by Jiuzhang Biotech, Nature magazine conducted exclusive interviews with Mr. Zhang Jie, the inventor, Professor Chen Xiaoguang from the Institute of Materia Medica of the Chinese Academy of Medical Sciences who is in charge of the research on the anti-tumor mechanism, and Professor Li Wenbin from the Department of Glioma at Beijing Shijitan Hospital who is the main person in charge of the glioma clinical trial.

[Patient Recruitment] Phase I Clinical Trial on the Safety, Tolerability and Pharmacokinetics of CHA for Injection in the Treatment of Advanced Malignant Gliomas